ロード中...
Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations
Dasatinib is a BCR-ABL inhibitor with 325-fold higher potency than imatinib against unmutated BCR-ABL in vitro. Imatinib failure is commonly caused by BCR-ABL mutations. Here, dasatinib efficacy was analyzed in patients recruited to phase 2/3 trials with chronic-phase chronic myeloid leukemia with o...
保存先:
| 出版年: | Blood |
|---|---|
| 主要な著者: | , , , , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
American Society of Hematology
2009
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4916940/ https://ncbi.nlm.nih.gov/pubmed/19779040 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2009-04-214221 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|